Incorporating Exercise Training Into Cardio-Oncology Care: Current Evidence and Opportunities: State-of-the-Art Review
Overview
Authors
Affiliations
Cancer treatment-induced cardiotoxicities are an ongoing concern throughout the cancer care continuum from treatment initiation to survivorship. Several "standard-of-care" primary, secondary, and tertiary prevention strategies are available to prevent the development or further progression of cancer treatment-induced cardiotoxicities and their risk factors. Despite exercise's established benefits on the cardiovascular system, it has not been widely adopted as a nonpharmacologic cardioprotective strategy within cardio-oncology care. In this state-of-the-art review, the authors discuss cancer treatment-induced cardiotoxicities, review the existing evidence supporting the role of exercise in preventing and managing these sequelae in at-risk and affected individuals living after cancer diagnoses, and propose considerations for implementing exercise-based services in cardio-oncology practice.
Cancer Diagnosis, Physical Activity, and Heart Disease Risk.
Stamatakis E, Koemel N, Biswas R, Ahmadi M JACC CardioOncol. 2025; 6(6):890-892.
PMID: 39801641 PMC: 11712014. DOI: 10.1016/j.jaccao.2024.11.002.
The role of physical exercise in cancer therapy-related CV toxicity.
Mattioli A, Bucciarelli V, Gallina S Future Cardiol. 2025; 21(3):131-134.
PMID: 39779253 PMC: 11875471. DOI: 10.1080/14796678.2025.2451530.
The Digital Revolution in Medicine: Applications in Cardio-Oncology.
Echefu G, Batalik L, Lukan A, Shah R, Nain P, Guha A Curr Treat Options Cardiovasc Med. 2024; 27(1).
PMID: 39610711 PMC: 11600984. DOI: 10.1007/s11936-024-01059-x.
Anthracycline Cardiotoxicity in Adult Cancer Patients: State-of-the-Art Review.
Camilli M, Cipolla C, Dent S, Minotti G, Cardinale D JACC CardioOncol. 2024; 6(5):655-677.
PMID: 39479333 PMC: 11520218. DOI: 10.1016/j.jaccao.2024.07.016.
Cardioprotection strategies for anthracycline cardiotoxicity.
Moreno-Arciniegas A, Cadiz L, Galan-Arriola C, Clemente-Moragon A, Ibanez B Basic Res Cardiol. 2024; 120(1):71-90.
PMID: 39249555 PMC: 11790697. DOI: 10.1007/s00395-024-01078-6.